Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancer

Prior treatment

• Patients have received abdominal or pelvic radiotherapy;

Other illness

• Platinum-refractory/uncontrolled epithelial ovarian cancer;
• Suffering from other malignant tumors that have not achieved complete remission in the past 2 years;
• General conditions cannot tolerate cytoreduction;
• Severe hypersensitivity reactions (≥ grade 3) to paclitaxel or platinum and/or any of its excipients;

Other

• Mucous carcinoma or low-grade serous carcinoma;
• Unable or unwilling to sign the informed consent form;
• Patients judged by the investigator to be unlikely to follow the research steps, restrictions and requirements.

• Patients with diagnosis of epithelial ovarian carcinoma, peritoneal carcinoma, or fallopian tube carcinoma within 3 lines recurrence;
• Recurrence occurred within 6 months since platinum-based chemotherapy;
• R0 ideal debulking in initial surgery; PET-CT indicate the recurrence lesion is almost in abdominal cavity, which is isolated and not exceed 5 sites, and the ascites is less than 500ml;
• ECOG/WHO Performance score of 0 to 1;
• Hematology function: Leukocyte≥ 3,5x10⁹/L, neutrophil≥ 1,5x10⁹/L, platelets ≥ 100x10⁹/L;
• No Renal insufficiency: serum creatinine \< 1,5 time the normal limit, creatinine clearance \> 60 mL/min;
• No hepatic failure: bilirubin ≤ 1,5 time the Normal limit;
• Patients with good compliance;
• Patients having read, signed and dated Informed consent before any study procedure.